Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Treasury Shares (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Treasury Shares readings, the most recent being $2.0 million for Q1 2026.

  • On a quarterly basis, Treasury Shares fell 6.19% to $2.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.0 million, a 6.19% decrease, with the full-year FY2025 number at $2.1 million, up 3407.27% from a year prior.
  • Treasury Shares hit $2.0 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $2.1 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.4 million in Q4 2023 to a low of $59137.0 in Q4 2024.
  • Median Treasury Shares over the past 5 years was $2.0 million (2026), compared with a mean of $1.7 million.
  • Biggest five-year swings in Treasury Shares: plummeted 97.53% in 2024 and later skyrocketed 3407.27% in 2025.
  • Kiniksa Pharmaceuticals International's Treasury Shares stood at $1.7 million in 2022, then surged by 37.56% to $2.4 million in 2023, then plummeted by 97.53% to $59137.0 in 2024, then skyrocketed by 3407.27% to $2.1 million in 2025, then dropped by 3.2% to $2.0 million in 2026.
  • The last three reported values for Treasury Shares were $2.0 million (Q1 2026), $2.1 million (Q4 2025), and $2.2 million (Q3 2025) per Business Quant data.